Can Nanomedicine Rescue Stalled Rare Drugs?

A new nanoparticle platform seeks to solve stubborn formulation hurdles in rare disease drug development

11 Feb 2026

In the race to treat rare diseases, the spotlight often falls on breakthrough molecules. But a quieter shift is underway. Some companies are betting that how a drug is delivered can matter just as much as what it is.

Oncotelic Therapeutics and its partner Sapu Nano are leaning into that idea with a nanomedicine platform called Deciparticle. The goal is straightforward: take compounds that are difficult to formulate and make them easier to use in the clinic.

For many orphan drug candidates, the science works on paper. The problem comes later. Poor solubility, instability, or uneven absorption can stall a program that otherwise shows promise. In rare disease, where patient populations are small and funding is tight, those delays can be costly.

Deciparticle wraps challenging compounds into ultra small injectable particles. By shifting away from pills and toward intravenous delivery, the platform aims to send more of the drug directly into circulation. The hope is more predictable exposure and less variability than oral dosing can bring.

The first test case is Sapu003, an injectable form of everolimus. The oral version of the drug has shown inconsistent absorption in some settings. Developers believe an IV nanomedicine format could offer tighter control over pharmacokinetics. Sapu003 is now entering early clinical trials, where researchers will assess safety, tolerability, and drug exposure. Any clinical benefit remains to be proven.

Company leaders frame Deciparticle not as a miracle fix, but as a reusable tool. In theory, it could be applied to other complex compounds in their pipeline. That flexibility is part of the appeal.

Across biotech, delivery platforms are drawing fresh interest in partnering talks. A system that can support multiple assets may raise the value of a pipeline without sending teams back to the discovery lab.

There are still hurdles ahead, including regulatory scrutiny and the realities of scaling up manufacturing. Yet early activity around nanomedicine suggests that formulation science is gaining ground.

For rare disease developers, the message is clear. Innovation is not only about finding new drugs. It is also about making the ones we have work better for the patients who need them most.